TIVC
Valion Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.26
−10.46%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- +39.2%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -40.8%
- EBITDA
- -47.7%
- EBIT
- -39.5%
- Net income
- -57.0%
- EPS
- +60.1%
- Free cash flow
- -32.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026